Getty Images
With just a few tweaks, this could have been a stellar release on a small study about the benefits of high doses of vitamin D on arterial stiffness. Arterial stiffness is a cause of atherosclerosis, a thickening and stiffening of the arterial wall, and is related to high blood pressure or hypertension.
The release presents many of the necessary caveats, avoids disease mongering and unjustifiable language, and does a nice job describing what the researchers did to reach their conclusions. The release also does readers a service by explaining a relatively complex topic in terms that regular readers (and journalists) can understand.
The actual number of people who saw a benefit is missing, though, as is any mention of harms, any mention of other treatments for arterial stiffness, and any mention of how the study was funded or whether there were any conflicts of interest. We gave the release three stars because we felt these were mostly benign omissions. But, in the interest of keeping a high standard for writing strong scientific news releases, we make note of the omissions where they occurred.
The benefits of daily supplement vitamins are under more scrutiny than ever because of repeated large scale studies that show minimal if any health effects. This raises the bar for researchers wanting to present a persuasive case for the benefits of vitamin D or any other vitamin.
The release responsibly notes that obtaining more vitamin D is a potentially simple endeavor for most individuals. They can drink more milk, for example, or purchase a relatively inexpensive supplement.
The release quantifies the benefits in each group with this statement: “Two thousand IUs decreased stiffness by 2 percent in that timeframe. At 600 IUs, arterial stiffness actually increased slightly – .1 percent – and the placebo group experienced a 2.3 percent increase in arterial stiffness over the timeframe.”
But we’re concerned that the release did not describe any of the statistical testing results. The 2% decrease seen by the group that got 2,000 units per day was not statistically significant. Nor was there a statistical significance in any group that received smaller doses. A difference was only seen in the group that got the highest dose of 4,000 units per day. That distinction was not made clear.
Further, what does a 2% decrease in arterial stiffness mean in terms that would matter to a patient? The 2% decrease in reduced stiffness is a proxy or surrogate marker for a health outcome, but not one that tells us the actual impact on patient health.
On the plus side, the release explains that the study consisted of 70 participants, and that those taking the most vitamin D showed the greatest reduction in arterial stiffness — 10.4 percent in 4 months — but it does not say how many participants that was. The study does make it clear, however. The high-dose group included 18 people.
The release does not delve into the side effects of taking high doses of vitamin D over a long period of time. These side effects include kidney stones, which should have been addressed. The study does note, though, that no side effects were reported in the trial.
The release does not make any bold claims about the efficacy of using vitamin D to treat arterial stiffness, but sticks to reporting the facts of the study as they are known. It cites the researchers calling for a larger study:
“Now it’s time to do a larger-scale study, particularly in high-risk populations, and follow participants’ progress for longer periods, Dong and Raed say. “A year would give us even more data and ideas,” Raed adds.”
The researchers essentially say that results are encouraging and the results were published in the journal PLOS ONE. The authors note that the connection between vitamin D and arterial stiffness “might be potential contributors” to heart disease in a certain subset of African Americans.
The release does not hype the dangers of vitamin D deficiency or even heart disease in general, mentioning once and low in the release that heart disease is the leading cause of death in the U.S.
The release does not mention any particular funding source.
The release does not discuss any other options patients might have for dealing with arterial stiffness. It does note, however, that there are easy and inexpensive ways to add vitamin D to a person’s diet.
The release makes clear that it would be simple for almost anyone seeking to increase their vitamin D intake to do so. They can drink more milk, eat more yogurt, eat more greens like kale, take a supplement and so forth.
The release does not overplay its hand here, but does say that the study is “what appears to be the first randomized trial of its kind.” This is a difficult fact to establish but since they are essentially saying, “To the best of our knowledge” this is a first, we’ll give the release the benefit of the doubt here.
The tone of the release is carefully measured throughout, with the writer repeatedly using language like “might” and “appears to be.”
When the news release launches with a discussion of two huge studies and saying that…
Despite efforts by obstetrical organizations and other groups over the years to reduce cesarean surgeries,…
This release touts the end of the biggest clinical trial to date on the drug Xarelto…
Systematic, Criteria-Driven
Do you write news releases?
And want help?
We offer free pre-publication review of releases. SEE MORE →
We will not display your name or e-mail address on the site, nor will we share your e-mail address with any third parties.
Thank you for joining the HealthNewsReview.org mailing list. It’s a good way for you to stay up-to-date on what we’ve published, even if you forget to come to our website every day or every week.
-Gary Schwitzer, Publisher, HealthNewsReview.org
By submitting this form, you are granting: HealthNewsReview.org, University of Minnesota , Minneapolis, MN, 55455, United States, https://www.healthnewsreview.org permission to email you. You may unsubscribe via the link found at the bottom of every email. Emails are serviced by Mailchimp. (See their Email Privacy Policy for details.)
When the news release launches with a discussion of two huge studies and saying that…
Despite efforts by obstetrical organizations and other groups over the years to reduce cesarean surgeries,…
This release touts the end of the biggest clinical trial to date on the drug Xarelto…
Comments
We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.
We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like
When the news release launches with a discussion of two huge studies and saying that…
Despite efforts by obstetrical organizations and other groups over the years to reduce cesarean surgeries,…
This release touts the end of the biggest clinical trial to date on the drug Xarelto…